Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Ocular Therapeutix Inc (NASDAQ: OCUL) was $7.94 for the day, up 2.85% from the previous closing price of $7.72. In other words, the price has increased by $2.85 from its previous closing price. On the day, 1.64 million shares were traded. OCUL stock price reached its highest trading level at $7.95 during the session, while it also had its lowest trading level at $7.53.
Ratios:
Our analysis of OCUL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.59 and its Current Ratio is at 10.66. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 11, 2025, initiated with a Buy rating and assigned the stock a target price of $15.
TD Cowen Upgraded its Hold to Buy on June 20, 2024, whereas the target price for the stock was revised from $7 to $11.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 24 ’25 when Dugel Pravin sold 21,475 shares for $6.87 per share. The transaction valued at 147,533 led to the insider holds 3,520,318 shares of the business.
Heier Jeffrey S. sold 3,061 shares of OCUL for $21,029 on Feb 24 ’25. The Chief Scientific Officer now owns 265,998 shares after completing the transaction at $6.87 per share. On Feb 24 ’25, another insider, Kaiser Peter, who serves as the Chief Development Officer of the company, sold 3,009 shares for $6.87 each. As a result, the insider received 20,672 and left with 210,078 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 1262634752 and an Enterprise Value of 946317632. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.82 while its Price-to-Book (P/B) ratio in mrq is 3.97. Its current Enterprise Value per Revenue stands at 14.85 whereas that against EBITDA is -5.58.
Stock Price History:
The Beta on a monthly basis for OCUL is 1.47, which has changed by -0.18144327 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $11.77, while it has fallen to a 52-week low of $4.06. The 50-Day Moving Average of the stock is 2.97%, while the 200-Day Moving Average is calculated to be -4.55%.
Shares Statistics:
OCUL traded an average of 1.11M shares per day over the past three months and 1983670 shares per day over the past ten days. A total of 157.75M shares are outstanding, with a floating share count of 133.91M. Insiders hold about 15.79% of the company’s shares, while institutions hold 72.51% stake in the company. Shares short for OCUL as of 1740700800 were 12048382 with a Short Ratio of 10.85, compared to 1738281600 on 10872561. Therefore, it implies a Short% of Shares Outstanding of 12048382 and a Short% of Float of 7.61.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
